Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (21-30 of 335) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaSebastiano Buti, Angelica Sikokis, Andrea Ardizzoni
Future Oncology (London, England)|August 2, 2018
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)Alessandro Leonetti, Teresa Zielli, Sebastiano Buti
Tumori|May 28, 2020
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case reportTeresa Zielli, Letizia Gnetti, Sebastiano Buti
Current Research in Pharmacology and Drug Discovery|December 26, 2022
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative reviewGiulia Mazzaschi, Federico Quaini, Sebastiano Buti
The New England Journal of Medicine|March 6, 2018
Durvalumab in Stage III Non-Small-Cell Lung CancerMatteo Santoni, Nicola Battelli, Sebastiano Buti
Expert Review of Anticancer Therapy|December 8, 2020
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinomaMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo
Cancer Management and Research|October 6, 2018
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to dateMelissa Bersanelli, Francesco Leonardi, Sebastiano Buti
Annals of Translational Medicine|October 29, 2019
The way towards tailored treatment for metastatic renal cancer patients in the <i>omics</i> era: are we getting a "transcriptomic compass"?Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The New England Journal of Medicine|June 1, 2022
Reassessing Human Adipose TissueSebastiano Buti, Alessio Cortellini, Melissa Bersanelli
Human Vaccines & Immunotherapeutics|January 11, 2021
The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
Pageof 34

Showing results (21-30 of 335) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaSebastiano Buti, Angelica Sikokis, Andrea Ardizzoni
Future Oncology (London, England)|August 2, 2018
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)Alessandro Leonetti, Teresa Zielli, Sebastiano Buti
Tumori|May 28, 2020
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case reportTeresa Zielli, Letizia Gnetti, Sebastiano Buti
Current Research in Pharmacology and Drug Discovery|December 26, 2022
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative reviewGiulia Mazzaschi, Federico Quaini, Sebastiano Buti
The New England Journal of Medicine|March 6, 2018
Durvalumab in Stage III Non-Small-Cell Lung CancerMatteo Santoni, Nicola Battelli, Sebastiano Buti
Expert Review of Anticancer Therapy|December 8, 2020
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinomaMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo
Cancer Management and Research|October 6, 2018
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to dateMelissa Bersanelli, Francesco Leonardi, Sebastiano Buti
Annals of Translational Medicine|October 29, 2019
The way towards tailored treatment for metastatic renal cancer patients in the <i>omics</i> era: are we getting a "transcriptomic compass"?Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The New England Journal of Medicine|June 1, 2022
Reassessing Human Adipose TissueSebastiano Buti, Alessio Cortellini, Melissa Bersanelli
Human Vaccines & Immunotherapeutics|January 11, 2021
The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
Pageof 34